Effects of cardiovascular drugs on ATPase activity of P-glycoprotein in plasma membranes and in purified reconstituted form

Biochimica et Biophysica Acta - Biomembranes

Volumn 1369, Issue 1, 1998, Pages 85-93

  Rebbeor, James F ^a,b   Senior, Alan E ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b UNIVERSITY OF ROCHESTER   (United States)

Author keywords

ATPase; Drug P glycoprotein interaction; P glycoprotein

Indexed keywords

ADENOSINE TRIPHOSPHATASE; CARDIOVASCULAR AGENT; DIGITALIS; DILTIAZEM; GLYCOPROTEIN P; NIFEDIPINE; QUINIDINE; VERAPAMIL;

ANIMAL CELL; ARTICLE; CHO CELL; DRUG EFFECT; DRUG PROTEIN BINDING; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN PURIFICATION;

ADENOSINE TRIPHOSPHATASES; ANIMALS; CALCIUM CHANNEL BLOCKERS; CARDIOTONIC AGENTS; CELL MEMBRANE; CHO CELLS; CRICETINAE; DIGITALIS GLYCOSIDES; NALOXONE; P-GLYCOPROTEIN; PROGESTERONE; QUINIDINE;

ANIMALIA; DIGITALIS;

EID: 0032472791     PISSN: 00052736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0005-2736(97)00185-5     Document Type: Article

References (47)

1. [1] M.M. Gottesman, I. Pastan, Annu. Rev. Biochem. 62 (1993) 385-427.
2. [2] P. Gros, E. Buschman, Int. Rev. Cytol. 137C (1993) 169-197.
3. [3] U.A. Germann, Eur. J. Cancer 32A (1996) 927-944.
4. [4] P.D. Roepe, L.Y. Wei, M.N. Hoffman, F. Fritz, J. Bioenerg. Biomembr. 28 (1996) 541-555.
5. [5] R.M. Wadkins, P.D. Roepe, Int. Rev. Cytol. 171 (1997) 121-165.
6. [6] C.F. Higgins, Annu. Rev. Cell Biol. 8 (1992) 67-113.
7. [7] R.M. Wadkins, P.J. Houghton, Biochim. Biophys. Acta 1153 (1993) 225-236.
8. [8] E. Georges, F.J. Sharom, V. Ling, Adv. Pharmacol. 21 (1990) 185-218.
9. [9] J.M. Ford, Eur. J. Cancer 32A (1996) 991-1001.
10. [10) F. Thiebaut, T. Tsuruo, H. Hamada, M.M. Gottesman, I. Pastan, M.C. Willingham, Proc. Natl. Acad. Sci. U.S.A. 84 (1987) 7735-7738.
11. [11] C. Cordon-Cardo, J. O'Brien, D. Casals, L. Rittman-Grauer, J.L. Biedler, M.R. Melamed, J.R. Bertino, Proc. Natl. Acad. Sci. U.S.A. 86 (1989) 695-698.
12. [12] I. Sugawara, I. Kataoka, Y. Morishita, H. Hamada, T. Tsuruo, S. Itoyama, S. Mori, Cancer Res. 48 (1988) 1926-1929.
13. [13] A.M. Schinkel, J.J.M. Smit, O. van Tellingen, J.H. Beijnen, E. Wagenaar, L. van Deemter, C.A.A.M. Mol, M.A. van der Valk, B.C. Robanus-Maandag, H.P.J. te Riele, A.J.M. Berns, P. Borst, Cell 77 (1994) 491-502.
14. [14] A.H. Schinkel, E. Wagenaar, L. van Deemter, C.A.A.M. Mol, P. Borst, Am. J. Clin. Invest. 96 (1995) 1698-1705.
15. [15] A.G. Golman, T.W. Rall, A.S. Niles, P. Taylor, in: J.G. Hardman, L.L. Limbird, P.B. Molinoff, R.W. Ruddon, A.G. Gilman (Eds.), The Pharmacological Basis of Therapeutics, McGraw-Hill, New York, 1996, pp. 759-779, 809-874.
16. [16] N. Okamura, M. Hirai, Y. Tanigawara, K. Tanaka, M. Yasuhara, K. Ueda, T. Komano, R. Hori, J. Pharmacol. Exp. Ther. 266 (1993) 1614-1619.
17. [17] F.J. Sharom, X. Yu, J.W.K. Chu, C.A. Doige, Biochem. J. 308 (1995) 381-390.
18. [18] A.B. Shapiro, V. Ling, J. Biol. Chem. 269 (1994) 3745-3754.
19. [19] B. Sarkadi, E.M. Price, R.C. Boucher, U.A. Germann, G.A. Scarborough, J. Biol. Chem. 267 (1992) 4854-4858.
20. [20] A.E. Senior, M.K. Al-Shawi, I.L. Urbatsch, FEBS Lett. 377 (1995) 285-289.
21. [21] U.S. Rao, R.L. Fine, G.A. Scarborough, Mol. Pharmacol. 45 (1994) 773-776.
22. [22] B. Sarkadi, M. Muller, L. Homolya, Z. Hollo, J. Sepodt, U. Germann, M.M. Gottesman. E.M. Price, R.C. Boucher, FASEB J. 8 (1994) 766-770.
23. [23] G. Scarborough, J. Bioenerg. Biomembr. 27 (1995) 37-41.
24. [24] M. Al-Shawi, A.E. Senior, J. Biol. Chem. 268 (1993) 4197-4206.
25. [25] I.L. Urbatsch, B. Sankaran, J. Weber, A.E. Senior, J. Biol. Chem. 270 (1995) 19383-19390.
26. [26] M.K. Al-Shawi, I.L. Urbatsch, A.E. Senior, J. Biol. Chem. 269 (1994) 8986-8992.
27. [27] I.L. Urbatsch, M.K. Al-Shawi, A.E. Senior, Biochemistry 33 (1994) 7069-7076.
28. [28] S.V. Ambudkar, I. Lelong, J. Zhang, C.O. Cardarelli, M.M. Gottesman, I. Pastan, Proc. Natl. Acad. Sci. U.S.A. 89 (1992) 8472-8476.
29. [29] O.D. Gasko, A.F. Knowles, H.G. Shertzer, E.-M. Suolinna, E. Racker, Anal. Biochem. 72 (1976) 57-65.
30. [30] P.P. Van Veldhoven, G.P. Mannaerts, Anal. Biochem. 161 (1987) 45-48.
31. [31] A. Fabiato, F. Fabiato, J. Physiol. (Paris) 75 (1979) 463-505.
32. [32] D. Wessel, U.l. Flugge, Anal. Biochem. 138 (1984) 141-143.
33. [33] P.D. Jeffrey, J.F. Schildbach, C.Y. Chang, P.H. Kussie, M.N. Margolies, S. Sheriff, J. Mol. Biol. 248 (1995) 344-360.
34. [34] A.E. Aulabaugh, R.C. Crouch, G.E. Martin, A. Ragouzeos, J.P. Shockcor, T.D. Spitzer, R.D. Farrant, B.D. Hudson, J.C. Lindon, Carbohydr. Res. 230 (1992) 201-212.
35. [35] K.M. Kessler, D.T. Lowenthal, H. Warner, T. Gibson, W. Briggs, M.M. Reindenberg, N. Eng. J. Med. 290 (1974) 706-709.
36. [36] D. McTavish, E.M. Sorkin, Drugs 38 (1989) 19-76.
37. [37] J. Hung, P.L. Hackett, S.P. Gordon, K.F. Ilett, Clin. Pharmacol. Ther. 43 (1988) 466-670.
38. [38] K.O. Haustein, I. Assmann, G. Huller, Int. J. Clin. Pharmacol. Ther. Toxicol. 28 (1990) 458-461.
39. [39] J.R. Luderer, in: A. Goth (Ed.). Medical Pharmacology: Principles and Concepts., C.V. Mosby, St. Louis, 1984, pp. 419-459.
40. [40] D.M. Lieberman, R.A.F. Reithmeier, V. Ling, J.H.M. Charuk, H. Goldberg, K.L. Skorecki, Biochem. Biophys. Res. Commun. 162 (1989) 244-252.
41. [41] I.A.M. DeLannoy, M. Silverman, Biochem. Biophys. Res. Commun. 189 (1992) 551-557.
42. [42] Y. Tanigawara, N. Okamura, M. Hirai, M. Yasuhara, K. Ueda, N. Kioka, T. Komano, R. Hori, J. Pharmacol. Exp. Ther. 163 (1992) 840-845.
43. [43] S. Ito, C. Woodland, P.A. Harper, G. Koren, Life Sci. 53 (1993) 25-31.
44. [44] U. Mayer, E. Wagenaar, J.H. Beijnen, J.W. Smit, D.K.F. Meijer, J. van Asperen, P. Borst, A.H. Schinkel, Br. J. Pharmacol. 119 (1996) 1038-1044.
45. [45] R. Callaghan, J.R. Riordan, J. Biol. Chem. 268 (1993) 16059-16064.
46. [46] S. Orlowski, M.M. Lluis, J. Belehradek, M. Garrigos, Biochem. J. 317 (1996) 515-522.
47. [47] I.L. Urbatsch, A.E. Senior, Arch. Biochem. Biophys. 316 (1995) 135-140.